Jubilant Ingrevia vs Epigral vs Ami Organics: Which Stock Should You Track
- September 28, 2026
- Posted by: Neeraj Pandey
- Category: Market
Jubilant Ingrevia PE 33.85, mkt cap Rs 10,449 crore. Epigral PE 16.88, mkt cap Rs 4,574 crore. Ami Organics PE 69.16, mkt cap Rs 26,788 crore.
Quick Answer
Jubilant Ingrevia vs Epigral vs Ami Organics is a side-by-side comparison of three companies from the Chemicals space. On this comparison, Jubilant Ingrevia carries a market capitalisation of about Rs 10,449 crore against Rs 4,574 crore for Epigral and Rs 26,788 crore for Ami Organics, with return on equity of 8.89%, 14.94% and 21.54% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
Jubilant Ingrevia vs Epigral vs Ami Organics starts with the core numbers most investors compare within the Chemicals segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.
All three names sit in the Chemicals bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Click Here – Get Free Investment Predictions
Jubilant Ingrevia, Epigral and Ami Organics: Company Overview
Jubilant Ingrevia is a listed Indian company in the Chemicals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Epigral is a listed Indian company in the Chemicals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Ami Organics is a listed Indian company in the Chemicals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Jubilant Ingrevia vs Epigral vs Ami Organics: Valuation and Profitability Snapshot
| Metric | Jubilant Ingrevia | Epigral | Ami Organics |
|---|---|---|---|
| Market Cap (approx.) | Rs 10,449 crore | Rs 4,574 crore | Rs 26,788 crore |
| PE Ratio (TTM) | 33.85 | 16.88 | 69.16 |
| PB Ratio | 3.26 | 2.06 | 16.20 |
| Return on Equity (ROE) | 8.89% | 14.94% | 21.54% |
| EPS (TTM, Rs) | 19.38 | 62.82 | 47.31 |
| Dividend Yield | 0.76% | 0.47% | 0.08% |
| Debt to Equity | 0.25 | 0.26 | 0.02 |
| Book Value per Share (Rs) | 201.38 | 514.92 | 201.97 |
Check the Univest Screener for Live Data
On valuation, Jubilant Ingrevia trades at a PE of 33.85 and a PB of 3.26, Epigral at a PE of 16.88 and a PB of 2.06, while Ami Organics trades at a PE of 69.16 and a PB of 16.20. On return on equity, the three post 8.89%, 14.94% and 21.54% respectively, and on dividend yield they stand at 0.76%, 0.47% and 0.08%.
Jubilant Ingrevia vs Epigral vs Ami Organics: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| Jubilant Ingrevia | Rs 1,310.49 crore | Rs 105.82 crore | +24.9% | +10.3% |
| Epigral | Rs 709.46 crore | Rs 99.74 crore | +15.4% | -3.6% |
| Ami Organics | Rs 331.47 crore | Rs 74.99 crore | +48.5% | -25.3% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter.
Download the Univest iOS App or Univest Android App to track Jubilant Ingrevia, Epigral and Ami Organics live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three chemicals names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.
Conclusion
Jubilant Ingrevia vs Epigral vs Ami Organics highlights how differently three companies in the same chemicals segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Jubilant Ingrevia vs Epigral vs Ami Organics
What is the market cap difference between Jubilant Ingrevia, Epigral and Ami Organics?
Ans. As of September 2026, Jubilant Ingrevia has a market cap of approximately Rs 10,449 crore, Epigral is at approximately Rs 4,574 crore, and Ami Organics is at approximately Rs 26,788 crore.
Which of the three has the highest PE ratio?
Ans. Among Jubilant Ingrevia, Epigral and Ami Organics, the PE ratios stand at 33.85, 16.88 and 69.16 respectively as of September 2026.
Which of the three has the highest ROE?
Ans. Jubilant Ingrevia, Epigral and Ami Organics post ROE of 8.89%, 14.94% and 21.54% respectively as of September 2026.
Which of these three stocks pays the highest dividend yield?
Ans. Jubilant Ingrevia, Epigral and Ami Organics carry dividend yields of 0.76%, 0.47% and 0.08% respectively.
What is the debt to equity ratio for Jubilant Ingrevia, Epigral and Ami Organics?
Ans. Jubilant Ingrevia carries a debt to equity of 0.25, Epigral of 0.26, and Ami Organics of 0.02.
Which of the three trades at the highest price to book value?
Ans. Jubilant Ingrevia, Epigral and Ami Organics trade at price to book ratios of 3.26, 2.06 and 16.20 respectively.
Is one of Jubilant Ingrevia, Epigral or Ami Organics better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
